VECTORAL PUBLISHING

**Research Article:** Quarterly Journal of Computational Technologies for Healthcare *Volume: 06*

# AI Governance Framework for Oncology: Ethical, Legal, and Practical Considerations

**Shivansh Khanna**
School of Information Sciences, University of Illinois at Urbana-Champaign

**Ishank Khanna**
Sri Aurobindo Medical College and PG Institute, Indore, India

**Shraddha Srivastava**
School of Information Sciences, University of Illinois at Urbana-Champaign

**Vedica Pandey**
Sri Aurobindo Medical College and PG Institute, Indore, India



## Abstract

**Background**: Existing general AI governance structures offer a basic framework; however, the specific complexities associated with cancer treatment and research call for a more customized strategy. This study proposes an extensive AI governance framework specifically designed for oncology, drawing upon existing models and adapting them to meet the distinct needs of this field.

**Methods**: The approach of the study involved a systematic analysis of existing AI governance frameworks and their applicability to oncology. We identified key elements from European ethics guidelines for trustworthy AI, the Universal Declaration of Human Rights, and various models focusing on ethical assessment, algorithmic impact, and innovation in AI. These elements were integrated into a proposed framework containing seven core domains: ethical and human rights compliance, technological robustness and safety, transparency and accountability, equity and non-discrimination, innovation and adaptive governance, stakeholder engagement and patient-centered care, and legal and regulatory compliance.

**Implications**: The proposed framework emphasizes ethical and human rights considerations, ensuring AI applications in oncology adhere to principles of beneficence, non-maleficence, autonomy, and justice. It advocates for robust quality assurance, continuous impact assessment, and transparent decision-making processes. The framework addresses the need for bias mitigation to ensure equity, encourages innovation through adaptive governance, and emphasizes the importance of stakeholder engagement. Legal and regulatory compliance, aligned with both national and international standards, forms a crucial aspect of the framework. Implementation strategies include regular audits, evaluations, and feedback loops to ensure effectiveness and adaptability.

VECTORAL
PUBLISHING

**Conclusion**: This study presents an AI governance framework to ensure that AI applications in oncology are not only technologically advanced but also ethically sound, legally compliant, and patient-centered.

***Keywords:*** *Adaptive Governance, AI Applications, Ethical Compliance, Oncology, Patient-Centered Care, Regulatory Compliance, Technological Robustnes*

# Introduction

The recent period has been characterized by a notable increase in the integration of AI technologies in the healthcare domain. This growth can largely be attributed to advancements in machine learning algorithms, the capacity for extensive data analysis, and the increased availability of large volumes of health-related data. AI applications are evident in several critical areas, including diagnostic procedures, the development of treatment plans, pharmaceutical research, personalized medicine, and patient care monitoring. In particular, AI algorithms are being used in the analysis of complex medical data, which is instrumental in the early and more accurate identification of diseases such as cancer, cardiovascular disorders, and diabetes. The utilization of AI in diagnostics has enabled healthcare professionals to interpret medical images and patient data with unprecedented precision, thus facilitating early intervention and improving treatment efficacy. In the realm of treatment protocol formulation, AI assists in analyzing vast datasets to identify effective treatment combinations, potentially leading to more personalized and targeted therapies. Moreover, in pharmaceuticals, AI expedites the drug discovery process by predicting molecular behavior and drug efficacy, thus reducing the time and cost associated with traditional drug development methods [1]. AI-powered tools and applications are being used to streamline administrative tasks in healthcare settings, such as scheduling, billing, and patient record management, thus reducing operational costs and improving the overall healthcare experience [2].

The evolution of AI in healthcare dates back to the late 20th century, with initial efforts focused on developing expert systems designed to mimic the decision-making abilities of human experts. One of the earliest examples was the development of MYCIN in the 1970s, an AI system designed to diagnose bacterial infections and recommend antibiotics [3]. However, it was the advent of more advanced machine learning techniques and the exponential increase in computational power in the 21st century that truly accelerated the growth of AI in healthcare. The 2010s witnessed a significant shift, with AI models increasingly trained on large datasets, leading to more sophisticated and accurate predictive models. Key milestones include the development of deep learning techniques for image recognition, greatly enhancing the ability of AI to interpret medical images such as X-rays and MRIs. The growth of wearable technology and mobile health apps also provided a wealth of data for AI analysis, further expanding its applications in monitoring and preventive healthcare [4].

AI's current applications in cancer care are significantly impacting diagnostics, treatment planning, and patient monitoring, underscoring a new era of precision oncology. Diagnostic tools leveraging AI have made impacts in the early and accurate detection of various cancers. For instance, AI algorithms are increasingly used in analyzing medical imaging such as mammograms, CT scans, and MRIs, offering enhanced accuracy in identifying malignancies often missed by the human eye. This is exemplified in tools like Google's DeepMind AI, which

has demonstrated proficiency in detecting breast cancer from mammograms with greater accuracy than human radiologists. In treatment planning, AI algorithms assist oncologists by analyzing vast datasets to recommend personalized treatment regimens. These systems consider individual patient profiles, including genetic information, and cross-reference them with large oncological databases to suggest the most effective treatment strategies. IBM's Watson for Oncology, for instance, provides evidence-based treatment options by analyzing the meaning and context of structured and unstructured data in clinical notes and reports.

**Figure 1. AI-Assisted Oncology Treatment Planning Process**




The unique challenges in oncology, such as the heterogeneous nature of cancer and the critical need for timely and precise interventions, necessitate specialized AI applications [5]. Each

cancer type and even individual tumors can present vast genetic variances, requiring highly personalized treatment approaches. AI helps address these complexities by enabling the analysis of large-scale genomic data, thereby facilitating the identification of specific mutation patterns and biomarkers critical for targeted therapies. This precision is crucial in developing effective treatment plans that are less invasive and more effective, minimizing side effects. Furthermore, patient monitoring in oncology poses distinct challenges due to the need for continuous and detailed tracking of tumor progression and response to treatment. AI-driven wearable devices and mobile apps are increasingly used for real-time patient monitoring, providing vital data on patient health parameters and treatment responses. This continuous flow of data aids in timely intervention, adjusting treatments as needed, and enhances patient engagement in their care process [6].

The use of AI in oncology presents ethical, legal, and practical challenges that need careful consideration. Key concerns include data privacy, with the need to secure cancer patients' sensitive medical information, adhering to regulations like GDPR and HIPAA. Bias in AI algorithms is another issue, potentially leading to unfair treatment recommendations if training data lacks diversity. Addressing this involves ensuring varied data and monitoring for biases. Transparency and accountability in AI systems are crucial for trust, necessitating 'explainable AI' that clarifies decision-making processes for healthcare providers and patients. Additionally, integrating AI into healthcare systems poses practical challenges, requiring training for healthcare professionals and ensuring equitable access to technology [7].

The establishment of an AI governance framework in oncology is vital for several reasons. First and foremost, it ensures the ethical use of AI technologies, addressing critical issues such as patient consent, privacy, and equitable use of AI. This is important in oncology, where decisions based on AI can significantly impact patient health outcomes. Additionally, such a framework is essential for maintaining data privacy and security. Given that oncology involves handling sensitive patient health information, a governance framework helps ensure compliance with data protection laws like GDPR in the EU and HIPAA in the US. This involves setting standards for data handling, storage, and security to protect against potential breaches that could have devastating consequences for patients. Given that AI algorithms can develop biases based on their training data, in oncology, this could result in unequal or inappropriate treatment recommendations. Governance frameworks provide guidelines for creating unbiased systems and mandate continual monitoring and correction of any biases.

## AI Governance Framework for cancer care

The proposed ai governance framework for cancer care is structured to address the challenges and considerations inherent in integrating ai into oncology practices. It encompasses several key areas:

Firstly, the framework focuses on ethical and human rights compliance, incorporating ethical principles from established guidelines and aligning ai technologies with human rights standards. This includes ensuring respect for patient dignity, privacy, and equality. In the area of technological robustness and safety, the framework emphasizes the need for quality assurance, mandating rigorous standards for the safety and accuracy of ai technologies. It also involves continuous monitoring and assessment to identify and mitigate unexpected impacts on patient care and outcomes.

Transparency and accountability are also central to the framework. It aims to make ai algorithms' decision-making processes understandable and explainable to healthcare professionals and patients. Additionally, the framework sets out guidelines for accountability in ai-driven decisions, including human oversight and intervention.

The framework addresses equity and non-discrimination through strategies to identify and mitigate biases in ai systems, striving to ensure equitable treatment across diverse patient populations.

Figure 2. Proposed AI Governance Framework in Oncology




Innovation and adaptive governance are encouraged through agile policy development, adapting governance policies in response to rapid technological advancements. Collaboration between healthcare providers, researchers, and developers is promoted to foster innovation while upholding ethical standards.

Stakeholder engagement and patient-centered care are highlighted, involving a range of stakeholders in the development and review of ai systems. The framework aims to prioritize patient needs and preferences in ai development and application. The framework emphasizes legal and regulatory compliance. It ensures ai applications comply with existing healthcare and data protection laws and advocates for new legal frameworks to address ai's unique challenges in oncology. Regular audits, evaluations, and feedback loops are established to ensure ongoing compliance and improvement of ai applications. This framework represents an effort to address ethical, technical, legal, and social challenges in the application of ai in oncology.

### *1. Ethical and Human Rights Compliance*

#### Integration of Ethical Principles (European ethics guidelines for trustworthy AI, Ethically aligned design) [8]:

The High-Level Expert Group on Artificial Intelligence, convened for the European Commission, has drafted the Ethics Guidelines for Trustworthy AI. The guidelines are rooted in the European Union Charter of Fundamental Rights and introduce a layered approach to trustworthy AI, emphasizing its significance in governance frameworks. At the apex of this structure are ethical principles anchored in fundamental human rights: respect for human autonomy, harm prevention, fairness, and explicability. These principles advocate for an AI decision-making process that is understandable and fair, especially in contexts marked by diverse interests and objectives. To guarantee fairness, the guidelines underscore the importance of transparency, traceability, and auditability in AI systems, while also stressing the need for special consideration towards vulnerable groups and situations characterized by power or information asymmetries, such as those between employers and employees or businesses and consumers [8].

The framework's second tier outlines key requirements for AI systems or services across their lifecycle. These include human agency and oversight, technical robustness and safety, privacy and data governance, transparency, diversity, non-discrimination and fairness, social and environmental wellbeing, and accountability. These elements are interconnected in a full-mesh network, each holding equal importance. Oversight is highlighted, suggesting governance mechanisms like human-in-the-loop (HITL), human-on-the-loop (HOTL), or human-in-command (HIC) approaches. The combination between “privacy and data governance” and “diversity, non-discrimination, and fairness” is crucial, especially to prevent historical biases and inadequate data governance. The guidelines also recommend impact assessments both prior to and during AI development for accountability. The model advocates for a process-oriented approach in implementing these requirements, encompassing both technical and non-technical methods. Non-technical approaches include legislation, corporate guidelines, codes of conduct, policies, performance indicators, and standards, considering AI users, consumers, organizations, research institutions, and governments as stakeholders. These standards also envision certification for organizations that produce AI systems in line with transparency, accountability, and fairness standards. The certifying entity could facilitate communication with industry and public oversight groups, sharing best practices and addressing emerging ethical concerns. Finally, the base tier consists of operational recommendations for implementing the upper-tier requirements in specific systems.

**Table** 1. **Framework for Ethical AI Principles and Recommendations** in **European ethics guidelines for trustworthy AI, Ethically aligned design**

| **Tier** | **Ethical Principles** |
|---|---|
| **Top Tier** | - Respect for Human Autonomy |
| | - Harm Prevention |
| | - Fairness |
| | - Explicability |
| **Middle Tier** | - Human Agency and Oversight |
| | - Technical Robustness and Safety |
| | - Privacy and Data Governance |

| | |
|---|---|
| | - Transparency |
| | - Diversity, Non-discrimination, and Fairness |
| | - Social and Environmental Wellbeing |
| | - Accountability |
| **Base Tier** | - Implementing Upper-Tier Requirements |
| | - Process-Oriented Approach (Technical and Non-Technical Methods) |
| | - Stakeholder Consideration (Users, Consumers, Organizations, Research Institutions, Governments) |
| | - Standards and Certification for AI Systems |
| | - Communication with Industry and Public Oversight |
| | - Addressing Ethical Concerns and Best Practices |

The European Ethics Guidelines for Trustworthy AI, when applied to oncology, offer a comprehensive framework to ensure that AI advancements in cancer care are conducted in an ethical, transparent, and equitable manner. In the diagnostic arena, AI's capacity to analyze complex medical data can significantly augment the precision and efficiency of cancer detection and diagnosis. By adhering to the guidelines, developers and healthcare providers can ensure that these AI systems are not only effective but also respect the principles of human autonomy and harm prevention. For instance, AI tools that analyze imaging data to detect early signs of cancer must be developed and deployed in a way that upholds patient rights and enhances the diagnostic process without replacing the critical judgment of medical professionals. This approach aligns with the guidelines' emphasis on ensuring technical robustness and safety in AI applications, ensuring that these tools are reliable, accurate, and function under a wide range of conditions. Moreover, the application of AI in personalized cancer therapy demonstrates a commitment to the principles of fairness and explicability.

Sensitive patient data, such as genetic information and health records used to train AI systems, must be handled with the highest standards of privacy and security. This not only ensures compliance with legal standards but also fosters patient trust in AI-driven healthcare solutions. The guidelines' principles of diversity, non-discrimination, and fairness are pertinent in oncology. AI models in cancer care must be trained on diverse datasets to prevent the perpetuation of existing biases and ensure that AI-driven solutions are effective across different patient demographics. This approach is crucial in delivering equitable healthcare and avoiding disparities in cancer treatment outcomes. Additionally, the guidelines underscore the importance of transparency and accountability in AI applications, which is vital in a high-stakes field like oncology. Implementing mechanisms such as impact assessments, regular audits, and maintaining human oversight (such as human-in-the-loop systems) are essential to monitor and evaluate the impact of AI applications in cancer care. These practices align with the guidelines' call for accountable and transparent AI systems, ensuring that AI's role in oncology is both ethically sound and aligned with the broader goals of patient care and healthcare equity.

### Human Rights Consideration (Universal declaration of human rights as a framework) [9]:

The Universal Declaration of Human Rights (UDHR), established in 1949, serves as a foundational framework for regulating artificial intelligence (AI) on an international scale. This necessity arises from the insufficiency of various existing ethics frameworks, which are often too specialized and lack the comprehensive reach required for global governance. The UDHR's adaptability across different cultures and its decades-long adoption make it a mature approach

for addressing the ethical challenges posed by AI. The United Nations Human Rights Council introduced modern adjustments to this framework in 2011. These were published as the UN Guiding Principles on Business and Human Rights. This document extends the human rights framework to the private sector, highlighting the roles and responsibilities businesses have in protecting human rights. It mandates governments to shield citizens from rights violations perpetrated by other states and non-state actors, including the private sector.

The human rights framework, as applied to AI, emphasizes the central importance of the individual in governance and society. This approach is geared towards addressing potential impacts of AI, which include a range of rights like equal protection and non-discrimination to ensure bias-free data and fair machine-based decisions; the right to life and personal security in relation to autonomous weapons systems; effective remedies for violations of rights, ensuring transparency, fairness, and accountability in AI systems; privacy rights, addressing the erosion of privacy in data-driven societies and the safeguarding of personal data; and the rights related to work and an adequate standard of living, guiding policy decisions around the displacement of human labor by AI technologies.

Table 2. The intersection of human rights principles and the advancing field of AI in oncology

| **Application Area in Oncology** | **UDHR Principles** | **Specifics in AI and Cancer Context** |
|---|---|---|
| **Personalized Medicine** | Confidentiality, Non-Discrimination, Equal Protection | AI algorithms analyze genetic data from cancer patients to tailor treatment regimens. Safeguards ensure confidentiality of sensitive information. Accessible to all segments of the population irrespective of socioeconomic status. |
| **Early Cancer Detection and Diagnosis** | Right to Life, Personal Security, Right to an Effective Remedy | AI systems analyze medical images (MRIs, CT scans) for early detection. Accuracy and reliability are crucial to prevent misdiagnoses. Transparent mechanisms needed for addressing AI system failures. |

The Universal Declaration of Human Rights (UDHR) finds specific applications in the field of oncology in the context of ethical AI use for cancer treatment and research. One notable application is in personalized medicine, where AI algorithms are used to analyze genetic data from cancer patients. These algorithms can predict how individuals will respond to different treatments, thus enabling tailored therapy regimens that maximize efficacy and minimize harmful side effects. The collection and analysis of sensitive genetic information must be conducted with stringent safeguards to ensure that patients' personal data remains confidential and is not misused. Furthermore, under the principles of non-discrimination and equal protection, there's an imperative to ensure that these advanced AI-driven treatments are accessible to all segments of the population, irrespective of socioeconomic status, to avoid creating disparities in healthcare outcomes.

Another significant application of the UDHR in oncology is in the use of AI for early cancer detection and diagnosis. AI systems, through sophisticated image processing algorithms, can analyze medical images like MRIs and CT scans to identify potential cancerous growths with high accuracy, often exceeding human performance. This capability can perform early cancer detection, leading to earlier interventions and better survival rates. However, this technological

advancement brings to the forefront the UDHR principles concerning the right to life and personal security. The accuracy and reliability of these AI systems are paramount, as misdiagnoses can lead to either unnecessary treatments or missed cancer diagnoses, both of which have severe implications for patient health and well-being. Moreover, the right to an effective remedy is crucial in cases where AI systems might fail or err, necessitating transparent, fair, and accountable mechanisms to address and rectify such failures.

### *2. Technological Robustness and Safety*

#### Quality Assurance (Software requirement model for the ethical assessment of robots) [10]:

The Software Requirement Model proposed by Millar in 2016 for the ethical assessment of robots emphasizes the integration of ethical considerations into the design and development process of robotic systems [10]. This model views ethics not just as a set of guidelines but as a dynamic social enterprise that actively shapes the interaction between humans and robots. Central to this model are five major rules. Firstly, it requires a balance between the designer's intentions and user needs, focusing on minimizing potential harm. This involves a proactive approach to anticipate and mitigate any adverse effects robots may have on users. Secondly, the model advocates for the use of user-centered ethical evaluation tools for AI systems. These tools must employ design methodologies that can identify and address the impacts of robots on human values in various use contexts. This approach ensures that the design of robots is aligned with the ethical expectations and cultural norms of their intended users.

The third rule involves incorporating the psychology of user-robot relationships into the ethical evaluation. This includes understanding variables like the user's emotional state, which is crucial in contexts where robots interact closely with humans, such as in healthcare or personal assistance. Fourthly, the model calls for compliance with the Human-Robotics Interaction Code of Ethics, ensuring that robotic designs adhere to established ethical standards. The model stresses the importance of designers being well-versed in both acceptable and unacceptable design features. This could be achieved by including ethicists in design teams, ensuring a diverse and ethically informed perspective in the development process. The implementation of this model could serve as an early warning system, signaling the need for intervention, such as a 'red button' mechanism in robotics projects, to safeguard against ethical transgressions.

One specific application of Software Requirement Model is in the domain of robotic surgery. Under this model, rigorous standards for quality and safety are established, necessitating thorough testing and validation of the robotic systems for their accuracy and reliability. This involves not only technical evaluations but also assessments of how these systems interact with human operators, such as surgeons, and the patients themselves. For instance, in procedures like tumor removals or biopsies, the precision of robotic arms is critical to avoid damaging surrounding healthy tissues. Therefore, the model demands extensive simulation and real-world testing scenarios to validate the performance of these systems. Additionally, the model mandates continuous monitoring and updating of these systems to ensure they adapt to new surgical techniques and evolving medical knowledge, thus maintaining high standards of patient care and safety.

| Table 3. Software Requirement Model by Millar for the ethical assessment of robots in the field of oncology and robotic surgery | | |
|---|---|---|
| **Rule** | **Description** | **Specific Application in Oncology and Robotic Surgery** |
| **1. Balance between Designer's Intentions and User Needs** | Minimizing potential harm by anticipating adverse effects. | In robotic surgery, ensuring the design minimizes risks to patients. Rigorous testing for precision in tumor removals or biopsies. |
| **2. User-Centered Ethical Evaluation Tools** | Design methodologies that address impacts on human values. | AI algorithms in cancer diagnostics should be tested for accuracy and bias across diverse patient groups, adhering to cultural and ethical norms. |
| **3. Incorporating Psychology of User-Robot Relationships** | Understanding user emotions in close human-robot interactions. | Assessing how robotic systems in healthcare emotionally engage with patients and healthcare professionals. |
| **4. Compliance with Human-Robotics Interaction Code of Ethics** | Adhering to ethical standards; including ethicists in design teams. | Ensuring ethical design in robotic surgery, with diverse teams for informed perspectives. Includes a 'red button' mechanism for ethical transgressions. |
| **5. Continuous Monitoring and Updating** | Adapting to new techniques and medical knowledge. | Regular updates and monitoring of robotic systems and AI in diagnostics to maintain high standards of patient care and adapt to evolving medical practices. |

Another application of this model in cancer care is in the use of AI for diagnostic purposes, such as the interpretation of medical imaging. The quality assurance aspect of the model requires that AI algorithms used in diagnosing cancers from imaging studies, like MRIs or CT scans, undergo rigorous validation processes. This includes not only their accuracy in detecting malignancies but also their reliability across diverse patient populations and different types of cancers. The model insists on the inclusion of diverse datasets in the training of these AI systems to reduce biases and improve their diagnostic accuracy across various demographic groups. Moreover, the model calls for regular ethical assessments to ensure these technologies adhere to patient privacy standards and data protection regulations, considering the sensitivity of medical data. It also demands mechanisms for human oversight and intervention, ensuring that AI-assisted diagnoses are always subject to expert medical review. This approach not only enhances the trustworthiness of AI applications in oncology but also aligns with the overarching goal of patient-centered care.

### Continuous Monitoring and Impact Assessment (Algorithmic impact assessment) [11]:

The Canadian Government's Algorithmic Impact Assessment (AIA), established in 2020, is a component of the Government Directive on Automated Decision-Making, designed to assist organizations in assessing and mitigating the potential impacts of deploying AI systems. The AIA involves a questionnaire that examine various aspects of AI deployment. It examines the rationale behind using AI in decision-making processes and the specific capabilities encompassed by the system. A key focus of the assessment is on algorithm transparency and explainability, which are crucial for understanding how decisions are made and ensuring they

can be scrutinized. The assessment also categorizes systems based on their application areas, such as health, social assistance, or economic sectors. Other critical elements include the development and training processes of the AI system, the underlying system and data architecture, stakeholders involved, and the measures in place for risk mitigation.

The can be outlined in the following table, with a focus on its application in healthcare, specifically for AI used in patient diagnosis and triaging:

Table 4. **Continuous Monitoring and Impact Assessment process within the Canadian Government's Algorithmic Impact Assessment (AIA)**

| Component | Description | Application in Healthcare (Patient Diagnosis & Triaging) |
|---|---|---|
| **Algorithmic Impact Assessment (AIA)** | A comprehensive questionnaire-based tool to assess AI deployment, focusing on transparency, capabilities, and risk mitigation. | Evaluating AI systems in healthcare for their decision-making process, potential biases, and impacts on patient care. |
| **Impact Categorization** | Classifying the severity and reversibility of AI impacts into four levels, from reversible and brief (Level I) to irreversible (Level IV). | Assessing the extent to which AI diagnoses or triaging decisions can impact patient health, rights, and well-being. |
| **Transparency Requirements** | Mandating public notification and explanations about AI decisions to ensure AI systems are understandable and scrutinizable. | Informing patients and healthcare professionals about how AI is used in diagnoses, ensuring decisions are clear and accountable. |
| **Quality Assurance Measures** | Setting forth rules for testing, monitoring outcomes, data quality maintenance, and human oversight. | Ensuring AI systems in healthcare are rigorously tested for accuracy, and monitored for ongoing effectiveness and safety. |
| **Continuous Monitoring** | Regularly evaluating AI performance and outcomes in real-time. | Tracking and analyzing AI-generated diagnoses against actual patient outcomes to identify errors or deviations in healthcare settings. |
| **Impact Assessment** | Evaluating how AI applications affect various aspects of patient care, including ethical implications and the patient-caregiver relationship. | Assessing whether AI systems in triaging or diagnostics inadvertently discriminate against certain groups or impact the quality of patient care. |

The AIA categorizes the impacts of automated decision-making into four distinct levels, each corresponding to the severity and reversibility of the impact on individuals' rights, health, well-being, economic interests, and the sustainability of ecosystems. Level I encompasses impacts that are reversible and brief, while Level II deals with impacts that are reversible in the short term. Level III includes impacts that are difficult to reverse, and Level IV concerns irreversible impacts. This graded approach allows for understanding of the potential consequences of AI systems and facilitates the implementation of appropriate safeguards and remediation strategies. By quantifying the level of impact, the AIA enables organizations to prioritize areas where rigorous oversight and stringent controls are most needed, ensuring that the deployment of AI systems aligns with ethical principles and societal values [12].

The Directive on Automated Decision-Making, underpinning the AIA, emphasizes two main pillars: transparency and quality assurance. The transparency requirements mandate that the public be notified through relevant websites before decisions are made by the AI system. It also requires providing meaningful explanations to affected individuals about the decisions that impact them. This aspect of the directive ensures that the AI systems are not black boxes but rather tools whose functioning and decisions can be understood and scrutinized. On the quality assurance front, the directive sets forth rules to ensure thorough testing and monitoring of outcomes, maintenance of data quality, peer reviews, employee training, and contingency planning. It also mandates security measures, compliance with legal standards, and provisions for human intervention.

Continuous Monitoring and Impact Assessment aspect of the Algorithmic Impact Assessment is crucial for maintaining the safety, efficacy, and ethical integrity of AI applications. Continuous monitoring involves implementing systems that regularly evaluate the performance and outcomes of AI tools in real-time. For instance, in a hospital setting where AI is used for patient diagnosis, continuous monitoring would entail tracking the accuracy of AI-generated diagnoses against actual patient outcomes. This could involve analyzing data from patient records, feedback from healthcare professionals, and direct patient outcomes to assess the AI system's performance. Such monitoring is to identify any deviations or errors in the AI's decision-making process that could adversely affect patient care. Moreover, this process includes evaluating the AI system's adaptability to new medical information or changing patient demographics, ensuring that the system remains effective and relevant over time.

The Impact Assessment component of this approach involves an evaluation of how AI applications affect patient care and outcomes. This includes assessing the ethical implications of AI decisions, such as ensuring that AI-driven healthcare solutions do not inadvertently discriminate against certain patient groups. For example, an AI system used for triaging patients in an emergency room must be assessed for its impact on different patient demographics to ensure it does not prioritize one group over another unfairly. Impact assessment also involves examining how AI applications influence the patient-caregiver relationship.

### *3. Transparency and Accountability*

Transparent Decision-Making Processes (Intelligent model to regulate learning algorithms) [13]:
The intelligent model proposed by Buiten in 2019 offers a comprehensive strategy to combat biases in intelligent services. This model emphasizes the importance of evaluating the critical components of machine learning processes, which include data, testing algorithms, and decision models. The foundation of this proposal is the recognition that mere transparency of code is insufficient to ensure unbiased solutions. It acknowledges that biases can still be present, even when algorithms learn from vast datasets. One of the key assertions of this model is the inherent bias in data samples. It posits that all data sets come with built-in biases that must be acknowledged and addressed. To mitigate these biases, the model insists on rigorous checks for data validity, reliability, and appropriate data dependency. This approach is designed to ensure that the data used in machine learning processes is as unbiased and accurate as possible.

The intelligent model proposed by Buiten in 2019 for regulating learning algorithms, especially in the context of oncology, can be summarized in the following table:

Table 5. I**ntelligent model proposed by Buiten in 2019 for regulating learning algorithms** in cancer care

| Component | Description | Application in cancer care |
|---|---|---|
| **Evaluating Machine Learning Components** | Assessing data, algorithms, and decision models for biases. | Ensuring data used for cancer diagnosis and treatment recommendations are unbiased and accurate. |
| **Acknowledging Inherent Bias in Data** | Recognizing biases in data sets and addressing them through rigorous checks. | Carefully selecting and validating data sets used for patient diagnosis and treatment planning to avoid inherent biases. |
| **Testing Algorithms Comparatively** | Employing diverse algorithms and comparing performances post data validation. | Comparing multiple AI algorithms to identify the best approach for cancer diagnosis and treatment recommendations. |
| **Understanding Decision-Making Process** | Being aware of correlations and interactions in data that could lead to biases. | Analyzing how AI systems process patient data and identifying potential biases in treatment recommendations. |
| **Transparent Decision-Making in AI** | Ensuring AI decision-making is transparent and understandable. | Providing oncologists and patients with clear explanations of AI-driven recommendations, including the rationale and analysis behind them. |
| **Patient-Friendly Communication** | Communicating AI reasoning in a way that is understandable to patients. | Explaining AI treatment plans to patients in simple terms, with information on risks and benefits, to facilitate informed decision-making. |

In terms of testing algorithms, Buiten's model advocates for a diverse and comparative approach. It recommends employing a range of algorithms and analyzing their performance against each other. However, this comparative testing should only be conducted after the quality and integrity of the data have been established. This step is crucial for identifying and eliminating any residual biases that might have been overlooked during the data validation phase. The decision-making process is identified as a sensitive stage, where developers must be acutely aware of the correlations and interactions between different variables. The model warns that hidden relationships within the data can easily lead to biased outcomes, often in subtle and complex ways. It also acknowledges the increasing difficulty of identifying and rectifying these biases as algorithms become more complex, underlining the ongoing challenge in developing truly unbiased intelligent systems.

The implementation of transparent decision-making processes in AI algorithms, as outlined in the intelligent model for regulating learning algorithms, takes on critical importance. For oncologists and cancer patients, understanding the rationale behind AI-driven recommendations is essential for trust and effective treatment planning. In this context, AI algorithms are employed for various purposes, including diagnosis, prognosis, treatment recommendations, and personalized medicine strategies. The transparency in these algorithms is vital because it allows healthcare professionals to understand why a particular treatment is suggested or why a certain diagnostic conclusion is reached. For instance, if an AI system recommends a specific chemotherapy regimen over another, it should provide a clear explanation that details how it analyzed patient data, such as genetic information, tumor type,

and patient history, to arrive at its recommendation. This level of clarity is indispensable for oncologists to make informed decisions and to feel confident in integrating AI insights into their clinical judgments.

Similarly, for cancer patients, who often face complex and emotionally challenging treatment decisions, understanding the AI's advice is crucial. When an AI system is used to recommend a treatment plan, it should be able to communicate its reasoning in a patient-friendly manner. This might involve explaining, in simple terms, how the AI analyzed the patient's unique cancer profile, comparing it with large datasets of similar cases, to suggest a treatment that has shown the most promise for similar conditions. It is also essential for these AI systems to provide information about the potential risks and benefits of the recommended treatments in an easily understandable format. This approach ensures that patients are fully informed and can actively participate in their treatment decisions. The goal is to make AI a tool that not only enhances the accuracy and efficiency of cancer care but also supports the patient's journey by providing clarity and reassurance.

### Accountability Mechanisms (Ethical judgement model for codes) [14]:

The Ethical Judgment Model proposed by Bonnemains et al. in 2018 is an innovative approach to addressing ethical dilemmas in decision-making. The model is predicated on the understanding that ethical decisions are complex and cannot be effectively resolved using a single ethical framework. Recognizing this, the authors propose a formal logical model designed to be implemented by an agent (which could be an AI system or a human-agent interface) confronted with an ethical dilemma. This model is unique in its capacity not only to make decisions but also to explain them, thereby adding a layer of transparency and accountability often lacking in automated decision-making processes. The model leverages formal expression analyses, which are instrumental in revealing the subjectivity inherent in decision-making. By doing so, it underscores the often-overlooked fact that ethical decisions are not just about choosing the right action but also about understanding and articulating the reasoning behind that choice. This aspect is important in fields like AI ethics, where explicability is as crucial as the decision itself.

Table 6. **The Ethical Judgment Model proposed by Bonnemains et al. in 2018** and **its application in AI systems for cancer care**.

| **Component** | **Description** | **Application in Cancer Care AI Systems** |
|---|---|---|
| **Ethical Judgment Model Framework** | A logical model for addressing ethical dilemmas, capable of decision-making and explanation. | Evaluating AI-driven decisions in cancer diagnosis and treatment planning, providing transparent reasoning for choices made. |
| **Use of Ethical Frameworks** | Incorporating consequentialist ethics, deontological ethics, and the Doctrine of Double Effect. | Assessing AI recommendations based on their outcomes, moral duties, and unintended effects in cancer treatment. |
| **Decision Categorization** | Judgments as acceptable (⊤), unacceptable (⊥), or undetermined (?). | Structuring AI decisions in cancer care to classify their ethical acceptability and inform actions accordingly. |
| **Concepts of Decision, Event, Effect** | Analyzing the consequences and moral implications of actions. | Understanding the impact of AI recommendations on patient outcomes and ethical considerations in cancer care. |

| | | |
|---|---|---|
| **Accountability Mechanisms** | Establishing responsibility and oversight roles for healthcare professionals. | Creating guidelines for oncologists to evaluate AI suggestions, integrating AI analysis with professional judgment. |
| **Transparency and Explainability** | Articulating AI decision-making processes in understandable terms. | Ensuring AI systems explain treatment recommendations clearly, aiding oncologists and empowering patients in decision-making. |

The Ethical Judgment Model evaluates different potential decisions using three predominant ethical frameworks: consequentialist ethics, deontological ethics, and the Doctrine of Double Effect. The model formalizes various ethical scenarios into judgment functions, which yield one of three possible outcomes: acceptable ($\top$), unacceptable ($\bot$), or undetermined (?). This categorization provides a structured way of assessing the ethicality of a decision, accommodating the complexities and nuances of real-world scenarios. Additionally, the model considers the concepts of 'decision', 'event', and 'effect', which are integral to understanding the consequences and moral implications of any action.

The integration of the Ethical Judgment Model for codes into AI systems brings forth the critical need for robust accountability mechanisms. This aspect of the model addresses the ethical and practical complexities that arise from AI-driven decisions in cancer diagnosis, treatment planning, and patient care management. A key component of these accountability mechanisms is the development of clear guidelines that delineate the responsibility and oversight roles of healthcare professionals in the AI decision-making process. Such guidelines are essential to ensure that AI tools are used as aids to, rather than replacements for, human expertise and judgment. This involves establishing protocols for when and how human oversight should be exercised, including the circumstances under which healthcare professionals should intervene, override, or closely scrutinize AI recommendations. For instance, in complex cases where AI systems provide treatment recommendations, oncologists should have well-defined protocols to evaluate these suggestions, considering both the AI's analysis and their professional judgment and experience.

Furthermore, in cancer care, where treatment decisions can have life-altering consequences, the need for transparency and explainability in AI systems becomes paramount. Accountability mechanisms must therefore also include provisions for how AI systems articulate their decision-making process. This is crucial for oncologists to understand the rationale behind AI recommendations and for patients to comprehend the basis of the treatment plans suggested for them. For example, if an AI system recommends a particular chemotherapy regimen, it should provide an explanation that is medically sound and understandable, detailing how it arrived at this conclusion based on patient data and comparative analysis with similar cases. This level of clarity not only aids medical professionals in making informed decisions but also empowers patients to be active participants in their treatment journey.

### *4. Equity and Non-Discrimination*

#### Bias Mitigation Strategies (Avoiding biases and discrimination):

In their 2020 study, Lin et al. examine an innovative AI-assisted intervention aimed at mitigating implicit biases, employing a bidimensional approach. This framework enhances the effectiveness of bias-reduction strategies in complex decision-making environments. The first

dimension of this approach focuses on the types of information AI systems provide to users, categorized into descriptive (current state of affairs), predictive (likelihood of future states), and prescriptive (expected utility of an action) information. This classification guides how Knowledge-Based Systems (KBS) determine the necessity and manner of intervention, essentially basing decisions on simulated outcomes. The second dimension of the framework addresses the various phases in which an AI system can intervene: input-based (affecting the data fed into the system), output-based (altering the results provided by the system), and cognition-based (influencing the decision-making process of the user). This methodology, as proposed by Lin et al., (2020) holds significant potential for application across various industries and service sectors, enabling them to integrate these bias-reducing strategies into their internal processes [15]. It represents a step forward in the use of software for regulatory purposes, especially in fields where decision-making is heavily reliant on data interpretation and where the consequences of biased decisions can be profound.

In cancer care, the implementation of bias mitigation strategies, as proposed by Lin et al. in 2020, is important to ensure equitable treatment and care for diverse patient populations. Cancer is a disease that manifests differently across various demographics, and biases in AI systems can lead to disparities in diagnosis, treatment recommendations, and patient outcomes. To address this, cancer care institutions must implement robust procedures for identifying and mitigating biases within their AI systems. This involves a thorough analysis of the data sets used for training AI models, ensuring they are representative of the diverse patient populations they will serve. For instance, an AI system used for diagnosing skin cancer must be trained on a diverse set of skin tones to avoid biases that could lead to misdiagnoses in patients with darker skin. Additionally, ongoing monitoring and evaluation of AI decisions are crucial to detect any patterns of bias, such as consistently recommending less aggressive treatment options for certain demographic groups. This approach in identifying biases allows for timely interventions and adjustments to the AI systems, ensuring that they remain fair and unbiased in their function.

Table 7. **The bias mitigation strategies proposed by Lin et al. (2020) study** and it applications in **AI-assisted interventions in cancer care**.

| **Dimension** | **Aspect** | **Description** | **Application in Cancer Care** |
|---|---|---|---|
| **First Dimension** | Types of Information | Descriptive: Current state of affairs. Predictive: Likelihood of future states. Prescriptive: Expected utility of an action. | Utilizing AI to provide comprehensive insights on patient data, predict outcomes, and recommend treatments, ensuring these processes are free from bias. |
| **Second Dimension** | Phases of Intervention | Input-based: Affecting the data fed into the system. Output-based: Altering the results provided by the system. Cognition-based: Influencing user decision-making. | Implementing interventions at different stages: Ensuring diverse data sets for training AI (Input-based); Adjusting AI recommendations to counteract biases (Output-based); Educating healthcare providers on AI biases (Cognition-based). |
| **Bias Mitigation** | Application in AI Systems | Employing Lin et al.'s bidimensional approach to reduce biases in complex | Ensuring AI systems in cancer diagnosis are trained on diverse patient data; Continuously monitoring AI decisions |

| | | | |
|---|---|---|---|
| | | decision-making environments. | to identify bias patterns; Adjusting AI algorithms and recommendations based on ongoing evaluations. |

Moreover, the application of Lin et al.'s bidimensional approach in cancer care can further enhance the effectiveness of these bias mitigation strategies. The first dimension, involving the types of information provided by AI (descriptive, predictive, and prescriptive), can be leveraged to understand and rectify biases in how AI systems interpret patient data and predict outcomes. For example, predictive information can be analyzed to ensure that AI predictions do not disproportionately favor or disadvantage any patient group. The second dimension, focusing on the phases of intervention (input-based, output-based, and cognition-based), allows for targeted bias mitigation. Input-based interventions can ensure the diversity and inclusivity of training data sets, while output-based interventions can adjust AI recommendations to counteract detected biases. Cognition-based interventions can be used to educate healthcare providers on the potential biases of AI systems, promoting more critical and informed utilization of AI in clinical decision-making.

### *5. Innovation and Adaptive Governance*

#### Agile Policy Development (Ethical framework for automation using robotics) [16]:

The ethical framework proposed by Wright and Schultz in 2018 [16] addresses the interaction between various stakeholders and the integration of automation and AI in the workforce. This framework uniquely combines Stakeholder Theory with Social Contract Theory to establish ethical guidelines for the development, provision, and utilization of AI technologies. It identifies a broad range of stakeholders, including workers, the market, governments, the economy, and society at large, emphasizing the ethical implications of AI's impact on the job market and the relationships among these diverse groups. The framework is structured around several key steps: identifying stakeholders, analyzing the social contracts between them, assessing how these stakeholders are impacted by AI integration, and implementing actions to mitigate the risks associated with terminating or altering work contracts.

Table 8. **The ethical framework proposed by Wright and Schultz in 2018 integrates Stakeholder Theory with Social Contract Theory to address the ethics of AI integration in the workforce.**

| Step | Component | Description | Context |
|---|---|---|---|
| **1** | **Identifying Stakeholders** | **Recognizing all parties affected by AI.** | **Workers, market, governments, society.** |
| **2** | **Analyzing Social Contracts** | **Examining agreements and expectations related to AI.** | **Relationships and responsibilities.** |
| **3** | **Assessing Impact on Stakeholders** | **Evaluating AI's effects on employment and society.** | **Job market, labor practices, societal norms.** |
| **4** | **Implementing Mitigation Actions** | **Developing strategies to manage AI's workforce impact.** | **Support for affected workers, policy reforms.** |

One of the central goals of this framework is to enhance benefits for all stakeholders focusing on workers whose jobs or roles may be transformed by the introduction of AI into products and services. This aspect of the framework is pertinent, considering the varied and complex interests of different stakeholder groups and the labor concerns that arise with the adoption of

AI. The framework also fits seamlessly into the government policy-making process due to its comprehensive approach to stakeholder impact.

Table 9. **Ethical framework proposed by Wright and Schultz in 2018 for the integration of automation and AI in the workforce, and its application in agile policy development for** cancer care

| Aspect | Description | Application in cancer care |
|---|---|---|
| **Combination of Theories** | Integrating Stakeholder Theory with Social Contract Theory for ethical guidelines. | Addressing the impact of AI on various stakeholders in oncology, including healthcare workers, patients, and society. |
| **Stakeholder Identification** | Identifying a range of stakeholders impacted by AI integration. | Recognizing the roles and concerns of healthcare providers, patients, regulatory bodies, and the public in oncology AI. |
| **Social Contract Analysis** | Analyzing agreements between stakeholders and their implications. | Assessing the ethical implications of AI in patient care and the responsibilities of healthcare providers and AI developers. |
| **Impact Assessment and Mitigation** | Assessing stakeholder impact and implementing actions to mitigate risks. | Evaluating and addressing the effects of AI on cancer care practices, job roles, and patient outcomes. |
| **Agile Policy Development** | Developing governance policies that adapt to technological changes. | Creating flexible and evolving regulatory frameworks that keep pace with advancements in AI for cancer treatment and diagnostics. |
| **Continuous Feedback Loop** | Establishing communication between practitioners, developers, and patients. | Incorporating feedback from healthcare professionals and patients to inform ongoing policy revisions in oncology AI. |
| **International Collaboration and Standards** | Emphasizing global cooperation in setting guidelines and standards. | Facilitating international standards for AI in oncology to ensure consistent ethical practices and data sharing globally. |

Agile policy development, as part of the ethical framework for automation using robotics in oncology AI, is a crucial approach for managing the rapid pace of technological change in cancer care. The dynamic nature of AI and robotics in healthcare necessitates governance policies that are not only robust but also flexible enough to adapt to new developments and discoveries. In oncology, policies must be designed to accommodate continuous innovation while ensuring patient safety and ethical standards. This means that regulatory frameworks should be capable of evolving in tandem with technological advancements. For instance, as AI algorithms become more sophisticated in predicting cancer progression or treatment outcomes, governance policies need to be adjusted to address new ethical and safety concerns that may arise, such as data privacy, algorithmic transparency, and the reliability of AI predictions.

Another key aspect of agile policy development in oncology AI is the establishment of a continuous feedback loop between healthcare practitioners, AI developers, regulatory bodies, and patients. For example, as oncologists and other healthcare providers gain more experience with AI tools, their insights into the practical and ethical implications of these technologies can inform policy revisions. Similarly, patient feedback on their experiences with AI-driven care can provide perspectives on patient consent, privacy concerns, and the overall impact of AI on

patient outcomes. This ongoing dialogue ensures that policies remain relevant and effective in addressing the real-world complexities of integrating AI into cancer care. It also encourages the development of AI solutions that are not only technologically advanced but also patient-centered, aligning with broader healthcare goals.

Adaptive governance in oncology AI must also encompass international collaboration and standard-setting, given the global nature of healthcare technology development and cancer care. As AI technologies developed in one country are often deployed worldwide, international standards and guidelines play a crucial role in harmonizing practices and ensuring consistent ethical standards. This global approach facilitates the sharing of best practices, data, and research findings, which is valuable in oncology, where global collaboration can accelerate advancements in cancer treatment and care. Additionally, international governance frameworks can help mitigate risks associated with AI, such as biases in algorithms that may be influenced by the data sets predominantly from specific regions or populations.

### Collaborative Research and Development (Standardisation exchange model) [17]:

The Standardisation Exchange Model proposed by Lewis et al. in 2020 emphasizes the critical role of standardization in regulating AI technologies [17]. This model introduces a structured process of information exchange regarding standards among various functional entities in the AI value chain. These entities, classified according to their roles, include data providers, AI system creators, AI system operators, AI users, oversight authorities, and associate stakeholders. Each of these actors plays a specific role in the development and implementation of AI, and their collaboration is essential for establishing and maintaining standards that focus on creating trustworthy AI systems. The model highlights the benefits derived from each exchange of standard-related information, emphasizing how these interactions contribute to the overall reliability and ethical deployment of AI technologies.

**Table 10. The Standardisation Exchange Model proposed by Lewis et al. in 2020** and its a**pplication**s **in Cancer Care**

| **Component** | **Description** | **Application in Cancer Care** |
|---|---|---|
| **Structured Information Exchange** | Establishing a process for exchanging standard-related information among AI value chain entities. | Facilitating communication between healthcare providers, researchers, and AI developers to align AI tools with clinical needs and ethical standards. |
| **Role Classification** | Classifying entities based on their roles in the AI value chain. | Involving various stakeholders in cancer care, like oncologists, AI creators, and regulators, in the development and implementation of AI technologies. |
| **Focus on Trustworthy AI Systems** | Emphasizing the creation of reliable and ethical AI systems through standardization. | Developing AI systems for cancer diagnosis and treatment that are clinically accurate, ethically sound, and patient-centric. |
| **AI Product Certification** | Highlighting the importance of a rigorous evaluation process for AI systems. | Ensuring AI tools in cancer care meet established technical, ethical, safety, and privacy standards before deployment. |
| **Government and International Involvement** | Acknowledging the role of government bodies and | Collaborating with government agencies and international bodies to set and |

| | | |
|---|---|---|
| | international communities in standardization. | comply with regulatory frameworks in cancer care AI. |
| **Collaborative R&D Approach** | Encouraging collaboration in research and development. | Joining efforts between healthcare professionals, technologists, and researchers to innovate in AI-driven cancer treatment and diagnostics. |
| **Standardization of Practices and Technologies** | Standardizing practices and technologies for compatibility and integration. | Harmonizing data formats and protocols for seamless integration into clinical workflows and multi-center research in oncology. |

The model sheds light on potential areas for new standardizations, many of which are pertinent to the AI product certification process. This aspect underscores the importance of developing standards that not only ensure the technical proficiency of AI systems but also address ethical, safety, and privacy concerns. The focus on AI product certification within this model indicates a commitment to rigorous evaluation processes, ensuring that AI systems meet established criteria before being deployed. While the model primarily targets the industry, it also acknowledges the significant role of government bodies in the standardization process. This inclusion points to the necessity of government involvement in setting regulatory frameworks and ensuring compliance with ethical and safety standards. Additionally, the model advocates for the creation of an international community to discuss and develop these standards, recognizing that the impact and application of AI technologies are global.

In cancer care, the application of the Standardisation Exchange Model encourages a collaborative approach to research and development, involving healthcare providers, researchers, and technology developers. This collaboration is pivotal for fostering innovation in cancer treatment and diagnostics while upholding ethical standards. For instance, oncologists and cancer researchers bring clinical insights and patient-centric perspectives to the development of AI technologies. By working closely with technology developers, they can ensure that new tools, such as AI-driven diagnostic algorithms or treatment planning systems, are not only technologically advanced but also clinically relevant and sensitive to patient needs. This joint effort can lead to the creation of AI applications that accurately reflect the complexities of cancer care, such as tailoring treatment plans to individual patient profiles or identifying subtle patterns in tumor progression. By involving healthcare professionals in the development process, technology creators can gain a deeper understanding of the ethical implications of their work and incorporate safeguards to protect patient interests.

Additionally, the collaboration facilitated by the Standardisation Exchange Model in cancer care extends to the standardization of practices and technologies. Standardization is crucial in ensuring that new developments are compatible with existing systems and can be seamlessly integrated into current clinical workflows. For example, standardized data formats and protocols enable the sharing of patient data across different platforms, enhancing the ability of AI systems to learn from diverse datasets and improving their accuracy and reliability. This harmonization also facilitates multi-center research studies, allowing for larger, more diverse patient cohorts that can provide more comprehensive insights into cancer biology and treatment responses. Moreover, involving oversight authorities and regulatory bodies in these

collaborative efforts ensures that the developed technologies comply with legal and ethical guidelines, paving the way for smoother regulatory approvals and wider adoption.

### *6. Stakeholder Engagement and Patient-Centered Care*

#### Inclusive Stakeholder Consultation and Patient-Centered Approach:

In cancer care, the implementation of Artificial Intelligence (AI) necessitates a unique and inclusive stakeholder consultation process. This process should actively engage not just healthcare professionals, but also patients who are undergoing cancer treatment, survivors, and their families. The inclusion of legal experts is vital for navigating the complex legalities around patient data use and AI-driven decision-making. Ethicists are equally important to address the moral and ethical implications of AI in life-altering cancer care decisions. Technologists and AI developers must work closely with oncologists and radiologists to understand the needs of cancer diagnostics and treatment. For example, in developing an AI system for personalized chemotherapy regimens, input from oncologists would be critical to ensure that the AI's recommendations are clinically relevant, while patients' input would guide the system's approach to addressing individual side effects and quality-of-life concerns. Legal and ethical experts would ensure that such systems operate within legal boundaries and maintain patient dignity and autonomy.

A patient-centered approach in AI for cancer care emphasizes personalized treatment and active patient engagement. AI technologies should be developed with a focus on addressing specific patient needs, such as predictive tools for cancer prognosis that take into account a patient's genetic information, lifestyle, and treatment preferences. AI-driven tools could be used to predict a breast cancer patient's response to certain hormone therapies, factoring in her genetic makeup and previous responses to treatment. This approach not only personalizes treatment plans but also involves patients in their care decisions. Patient education tools using AI can be developed to provide understandable and relevant information about their condition, treatment options, and potential outcomes. This not only empowers patients but also helps in managing their expectations and reducing anxiety. AI interfaces for patient communication, such as chatbots or virtual assistants, should be designed to provide support and answer queries in a compassionate and empathetic manner, tailored to each patient's emotional and informational needs.

To ensure a patient-centric approach in AI for cancer care, continuous evaluation and adaptation based on real-world use are essential. This involves conducting ongoing trials and studies to assess the effectiveness and patient satisfaction with AI tools in various cancer care scenarios. AI systems used in radiology for detecting tumor progression should be regularly assessed for accuracy and improved based on feedback from both radiologists and patients. Feedback mechanisms should be integrated into these systems to capture patient experiences and outcomes. Moreover, the AI development process must include protocols for patient privacy and data security, ensuring that patient data is used ethically and responsibly. Regular ethical reviews and adherence to evolving legal standards are necessary to maintain the trust of patients and the broader healthcare community. Transparency in AI decision-making processes and outcomes is key to building and maintaining this trust.

*7. Legal and Regulatory Compliance*

### Alignment with National and International Regulations, Adaptive Legal Frameworks, Regular Audits, and Feedback Loops:

Ensuring that AI applications in oncology comply with existing legal frameworks and regulations is a challenge, requiring an understanding of both healthcare law and data protection statutes. National regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States, set strict standards for patient data privacy and security that AI systems must adhere to. Internationally, regulations like the General Data Protection Regulation (GDPR) in the European Union introduce additional layers of complexity, particularly around the processing of personal data and obtaining explicit consent. In the context of oncology, where patient data includes sensitive health information, AI applications must be meticulously designed to ensure compliance. An AI system used in cancer diagnosis must encrypt patient data to prevent unauthorized access and include mechanisms for patient consent before data is processed or shared. These applications must be regularly updated to reflect changes in regulations. This ongoing compliance demands close collaboration between legal experts, technologists, and healthcare providers to continuously monitor regulatory changes and adjust AI systems accordingly.

The rapid advancement of AI in oncology necessitates the development of adaptive legal frameworks that can keep pace with technological innovation. Current legal systems may not adequately address the unique challenges posed by AI, such as accountability for AI-driven decisions and the use of machine learning algorithms in patient care. Advocating for and contributing to new legal frameworks involves a concerted effort from multiple stakeholders, including legal experts specializing in healthcare technology, policymakers, AI developers, and oncology professionals. For example, the creation of guidelines for the ethical use of AI in cancer prognosis and treatment decision-making is crucial. These guidelines should consider how AI recommendations are integrated into clinical decision-making processes, ensuring that the final decisions remain under the purview of qualified medical professionals. Additionally, there is a need for legal frameworks that address the use of AI in clinical trials for new cancer therapies, ensuring that patient safety and ethical considerations are at the forefront.

The implementation and review of AI systems in oncology ensures these technologies are used effectively and responsibly. This involves not only the initial deployment of AI systems but also their ongoing evaluation and improvement. Regular reviews should be conducted to assess the performance of AI applications in clinical settings, focusing on accuracy, efficacy, and patient outcomes. For instance, an AI system used for predicting the efficacy of chemotherapy regimens should be periodically evaluated for its precision and impact on patient survival rates. This review process should also involve monitoring for any unintended biases in AI algorithms that could affect treatment recommendations.

Conducting regular audits and evaluations of AI systems in the field of oncology is essential to ensure their ongoing compliance with the established governance framework, which encompasses ethical standards, legal requirements, and clinical efficacy. These audits must be thorough and systematic, involving a detailed examination of AI algorithms, data usage, and decision-making processes. A key aspect of such evaluations is to assess how AI systems handle sensitive patient data, ensuring adherence to privacy laws and ethical guidelines for data protection. Moreover, the clinical efficacy of AI tools must be scrutinized; for instance, an AI

application used for predicting cancer treatment outcomes should be regularly evaluated for its accuracy and reliability against clinical outcomes. This involves statistical analysis of the AI's predictions compared to actual patient responses to treatment. Regular audits also serve to identify any biases or inaccuracies in the AI algorithms that could adversely affect patient care.

Establishing effective feedback loops is crucial for the continuous improvement of AI applications in oncology. These loops should encompass input from a broad range of stakeholders, including healthcare professionals, patients, caregivers, and AI developers. One key aspect is gathering feedback from patients who are directly affected by these AI systems. For example, patient-reported outcomes and experiences with AI-driven diagnostic tools or treatment planning systems can provide invaluable insights into the system's user-friendliness, effectiveness, and areas for improvement. Healthcare professionals, such as oncologists and nurses, can provide feedback on the clinical utility and integration of AI tools in their workflows. Additionally, regular sessions with AI developers and technologists are necessary to translate this feedback into technical improvements and updates. These feedback mechanisms should be structured and continuous, involving regular surveys, focus groups, and consultation sessions.

The crux of enhancing AI applications in oncology lies in the continuous improvement driven by stakeholder engagement. This requires not just collecting feedback, but actively engaging with stakeholders in the decision-making process regarding AI system updates and policy changes. For instance, patient advocacy groups could be involved in discussions about how AI is used in patient care planning, ensuring that patient preferences and values are reflected in AI-driven decisions. Similarly, collaboration with regulatory bodies and legal experts can help in understanding and adapting to changing regulations and ethical standards. It is also crucial to involve frontline healthcare workers in these discussions, as they can provide practical insights into the integration of AI tools in clinical settings. This approach to stakeholder engagement ensures that AI systems in oncology are not only technically advanced and compliant with regulations but are also aligned with the real-world needs and values of those they are designed to serve.

## Conclusion

The domain of Ethical and Human Rights Compliance in AI applications for oncology represents a fundamental pillar, ensuring that the deployment of AI technologies adheres to core ethical principles and respects human rights. By integrating guidelines such as the European ethics guidelines for trustworthy AI and the Universal Declaration of Human Rights, this domain seeks to embed values like human autonomy, harm prevention, fairness, and explicability into the fabric of AI systems. This integration is crucial in oncology, a field where decisions can have profound impacts on patient lives. The focus on human autonomy ensures that AI supports, rather than supplants, the decision-making capabilities of both patients and healthcare providers, thereby maintaining the human element in healthcare. The commitment to preventing harm aligns with the medical ethos of 'do no harm,' ensuring that AI technologies are developed and used in a way that minimizes risk to patients. Fairness ensures that AI decisions are free from biases and discrimination, thus upholding the principles of justice and equality. Explicability makes AI systems transparent and understandable, not just to healthcare professionals but also to patients who are increasingly becoming active participants in their care journey. This domain, therefore, establishes a framework where AI not only advances oncology

but does so in a manner that is ethically sound and human-rights oriented, placing the welfare and rights of patients at the forefront.

The AI-based cancer care domain emphasizes the need for establishing stringent standards for the quality and safety of AI technologies. These standards are essential in ensuring that AI tools are not only effective but also reliable and secure, minimizing the risk of errors that could have serious implications for patient care. The ethical assessment of these technologies forms a critical part of this process, scrutinizing AI tools to ensure they align with ethical standards and do not inadvertently cause harm. Continuous monitoring and impact assessment are key practices within this domain, allowing for the ongoing evaluation of AI applications in real-world settings. This proactive approach helps in identifying and addressing any unforeseen impacts or malfunctions of AI systems, ensuring that they continue to operate safely and effectively. Moreover, in the dynamic field of oncology, where new treatments and research findings are constantly emerging, the ability to rapidly update and adapt AI technologies is crucial. This domain, therefore, not only ensures that AI systems in oncology are built on a foundation of robustness and safety but also that they remain agile and responsive to the evolving landscape of cancer care, thereby maximizing their utility and minimizing potential risks.

Transparency and Accountability in AI applications within oncology seeks to bridge the gap between advanced technological capabilities and the ethical, transparent use of such technologies. The demand for AI algorithms to be transparent, understandable, and explainable is not just a technical requirement but also a moral imperative. In the sensitive field of oncology, where AI can influence life-altering decisions, it is essential that both healthcare professionals and patients can understand how AI systems arrive at certain conclusions or recommendations. This transparency fosters trust and enables informed decision-making, ensuring that AI serves as a tool for enhancement, not confusion or obfuscation. Accountability goes hand-in-hand with transparency. This domain advocates for clear guidelines that delineate responsibility in AI-driven decisions, emphasizing the need for protocols that ensure human oversight and intervention. Such measures ensure that despite the autonomy of AI systems, the ultimate responsibility for decisions lies with human professionals, maintaining a necessary check on the technology. This focus on accountability also means establishing clear lines of responsibility in cases where AI systems may malfunction or lead to adverse outcomes, ensuring that there are mechanisms for redressal and correction.

The endeavor to standardize ethical principles within AI applications in oncology presents significant challenges. The framework's commitment to ethical compliance hinges on transforming abstract ethical principles into concrete, measurable standards. However, the interpretation of these ethical principles can vary widely among stakeholders, including healthcare providers, patients, technologists, and policymakers. What is considered ethical in one cultural or social context may not align with perceptions in another, leading to potential conflicts. For instance, the principle of autonomy might be interpreted differently by patients prioritizing individual choice versus healthcare providers emphasizing evidence-based recommendations. Moreover, operationalizing such principles in the context of complex AI systems requires a deep understanding of both the technological aspects and the ethical implications. This challenge is further compounded in a field as sensitive and diverse as oncology, where decisions can have profound impacts on patient well-being and outcomes.

Establishing universally accepted ethical criteria in such an environment necessitates ongoing dialogue, negotiation, and adaptation, which can be a time-consuming and complex process.

The diverse and vast datasets involved in oncology, including genetic, demographic, and health records, increase the risk of inherent biases in AI algorithms. These biases can lead to unequal treatment recommendations, misdiagnosis, or overlooked symptoms in underrepresented groups. Effectively identifying and mitigating these biases is a significant challenge. The framework aims to standardize bias mitigation strategies, but the effectiveness of these strategies can vary based on the type of data, the nature of the AI application, and the specific clinical context.

Implementing an AI governance framework in oncology is resource-intensive. It requires not only the deployment of advanced technological infrastructure but also the continuous involvement of expert personnel across various domains, including AI development, healthcare, ethics, and legal compliance. In settings where resources are constrained, whether in terms of financial, technological, or human capital, the implementation of such a framework can be challenging. Smaller healthcare facilities or research institutions might struggle to allocate the necessary funding for state-of-the-art AI technologies or to hire experts in AI ethics and regulation. Continuous funding is also required to maintain, update, and improve AI systems, which can be a significant financial burden. Furthermore, the rapid pace of technological advancement in AI necessitates ongoing training and development for healthcare professionals, adding to the resource demands. These constraints can limit the accessibility and scalability of AI applications in oncology, potentially widening the gap between well-resourced and under-resourced healthcare systems.

The legal and regulatory aspects governing AI in healthcare are in a state of continuous evolution, creating a challenging environment for developers and healthcare providers. As AI technologies advance, so too must the legal frameworks that regulate their use, often lagging behind technological developments. This lag can create a regulatory grey area, where the applicability of existing laws to new AI applications is unclear. Regulations vary significantly across different regions and countries, adding another challenge for AI applications that are used globally.

Achieving the right balance between transparency and the inherent complexity of AI algorithms is a critical challenge. Making complex AI systems transparent and understandable to non-experts, such as patients, is essential for building trust and ensuring informed decision-making. However, the sophisticated nature of these algorithms can make this transparency difficult to achieve without oversimplifying the information, potentially leading to misunderstandings or misinterpretations about the AI's capabilities and limitations. This challenge is acute in oncology, where treatment decisions have significant implications for patient outcomes.

Tight regulations can create barriers to entry for new AI applications, hindering the development of potentially beneficial technologies. The challenge lies in finding a balance between maintaining high standards for safety and ethics and fostering an environment that encourages innovation and the exploration of new ideas. Regulatory frameworks need to be flexible enough to accommodate the rapid pace of technological advancements in AI while still protecting patient safety and privacy.

# References

[1] M. Chen and M. Decary, “Artificial intelligence in healthcare: An essential guide for health leaders,” *Healthc. Manage. Forum*, vol. 33, no. 1, pp. 10–18, Jan. 2020.
[2] S. Nikkhah and A. D. Miller, “AI in the family: Care collaboration in pediatrics as a testbed for challenges facing AI in healthcare,” 2021. [Online]. Available: http://francisconunes.me/RealizingAIinHealthcareWS/papers/Nikkhah2021.pdf.
[3] P. Roseline, C. J. M. Tauro, and N. Ganesan, “Design and development of fuzzy expert system for integrated disease management in finger millets,” *Int. J. Comput. Appl. Technol.*, vol. 56, no. 1, 2012.
[4] E. Shortliffe, *Computer-Based Medical Consultations: MYCIN*. Elsevier, 2012.
[5] I. S. Chua, M. Gaziel-Yablowitz, and Z. T. Korach, “Artificial intelligence in oncology: Path to implementation,” *Cancer*, 2021.
[6] V. Y. Londhe and B. Bhasin, “Artificial intelligence and its potential in oncology,” *Drug Discov. Today*, 2019.
[7] K. Bera, K. A. Schalper, D. L. Rimm, and V. Velcheti, “Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology,” *Clin. Oncol.*, 2019.
[8] A. I. Hleg, “Ethics guidelines for trustworthy AI,” *B-1049 Brussels*, 2019.
[9] F. Raso, H. Hilligoss, V. Krishnamurthy, C. Bavitz, and L. Y. Kim, “Artificial intelligence & human rights: Opportunities & risks,” *SSRN Electron. J.*, 2018.
[10] J. Millar, “An Ethics Evaluation Tool for Automating Ethical Decision-Making in Robots and Self-Driving Cars,” *Appl. Artif. Intell.*, vol. 30, no. 8, pp. 787–809, Sep. 2016.
[11] J. Metcalf, E. Moss, E. A. Watkins, R. Singh, and M. C. Elish, “Algorithmic Impact Assessments and Accountability: The Co-construction of Impacts,” in *Proceedings of the 2021 ACM Conference on Fairness, Accountability, and Transparency*, Virtual Event, Canada, 2021, pp. 735–746.
[12] J. P. Singh, “AI Ethics and Societal Perspectives: A Comparative Study of Ethical Principle Prioritization Among Diverse Demographic Clusters,” *Journal of Advanced Analytics in Healthcare Management*, vol. 5, no. 1, pp. 1–18, Jan. 2021.
[13] M. C. Buiten, “Towards Intelligent Regulation of Artificial Intelligence,” *European Journal of Risk Regulation*, vol. 10, no. 1, pp. 41–59, Mar. 2019.
[14] V. Bonnemains, C. Saurel, and C. Tessier, “Embedded ethics: some technical and ethical challenges,” *Ethics Inf. Technol.*, vol. 20, no. 1, pp. 41–58, Mar. 2018.
[15] Y.-T. Lin, T.-W. Hung, and L. T.-L. Huang, “Engineering equity: How AI can help reduce the harm of implicit bias,” *Philos. Technol.*, vol. 34, no. S1, pp. 65–90, Nov. 2021.
[16] S. A. Wright and A. E. Schultz, “The rising tide of artificial intelligence and business automation: Developing an ethical framework,” *Bus. Horiz.*, vol. 61, no. 6, pp. 823–832, Nov. 2018.
[17] D. Lewis, L. Hogan, D. Filip, and P. J. Wall, “Global challenges in the standardization of ethics for Trustworthy AI,” *J. ICT Stand.*, Apr. 2020.